摘要
目的观察胃癌合并2型糖尿病(T2DM)患者围术期甘精胰岛素治疗的临床疗效及安全性。方法将60例胃癌合并2型糖尿病患者随机分为G+A组(n=20),CSII组(n=20),MSII组(n=20)3个组。比较3种不同治疗方法在手术前后评价治疗后前3d内血糖变化水平,低血糖发生的次数、血糖达到预期指标的时间、术前血糖治疗的准备时间、平均住院时间等指标。结果连续治疗3d后血糖改善明显,与治疗前相比,空腹及睡前血糖水平值明显下降,差异有统计学意义(P<0.05)。治疗2d后G+A、CSII两组血糖水平的控制明显好于MSII组,差异有统计学意义(P<0.05)。G+A组与MSII组在血糖达到预期指标的时间、术前血糖治疗的准备时间、平均住院时间、低血糖发生的次数4项指标比较,差异有统计学意义(P<0.05)。结论在胃癌合并2型糖尿病患者围术期使用甘精胰岛素+门冬胰岛素对应血糖变化水平的控制明显好于常规胰岛素,同时在血糖达标的时间上也明显短于对照组,没有增加患者的并发症,与胰岛素泵的效果是一项既经济又安全理想的治疗方案。
Objective To observe the clinical efficacy and safety of gastric type 2 diabetes mellitus （T2DM） patients with perioperative insulin glargine treatment. Methods Sixty cases of diabetes were randomly divided into three groups [G＋A group （n=20）, CSII group （n=20）, MSII group （n=20）]. Blood sugar levels, the incidence of hypoglycemia, blood glucose time, preoperative preparation time, the average length of stay were compared. Results In G＋A group, CSII treatment group on day 3 compared with before treatment, fasting and bedtime blood glucose decreased significantly （P〈0.01）; from the 2nd day of G＋A group, CSII group was significantly better in controling blood glucose than in MSII group; blood glucose time, preoperative preparation time, hospital stay, frequency of hypoglycemia in G＋A group and MSII group hadstatistically significant （P〈0.01）. Conclusion Perioperative insulin aspart combined with insulin glargine, blood glucose control is significantly better than conventional multiple subcutaneous injection, while blood glucose is significantly reduced, thereby shortening the preoperative preparation time and the average length of stay, insulin glargine combined subcutaneous injection of insulin for perioperative patients with type 2 diabetes, is an economic, safe and reliable ideal intensive treatment program.
出处
《当代医学》
2012年第23期2-4,共3页
Contemporary Medicine
关键词
胃癌
2型糖尿病
围术期
甘精胰岛素
Gastric cancer
Type 2 diabetes
Perioperative period
Glargine
